紫杉醇联合曲妥珠单抗治疗表皮生长因子受体-2阳性可手术乳腺癌

Paclitaxel combined with trastuzumab in the treatment of operability breast cancer patients with human epi- dermal growth factor receptor.2 positive

目的探讨紫杉醇联合曲妥珠单抗治疗表皮生长因子受体-2（Her-2）阳性可手术乳腺癌的临床疗效及其安全性。方法22例Her-2阳性浸润性乳腺癌患者给予紫杉醇联合曲妥珠单抗每3周新辅助化疗方案治疗，并行根治性手术治疗，评价临床疗效及毒副反应。结果22例患者治疗后，完全缓解13例，部分缓解3例，稳定4例，进展2例，有效率为72．7％（16／22），疾病控制率为90．9％（20／22）；病理完全缓解12例（54．6％）。毒副反应主要表现为骨髓抑制和消化道反应。结论紫杉醇联合曲妥珠单抗治疗Her-2阳性可手术治疗的乳腺癌疗效较好，且安全，具有较高的病理完全缓解率及有效率。

Objective To explore the effect and safety of paclitaxel combined with trastuzumab in the treat- ment of operability breast cancer patients with human epidermal growth factor receptor-2 positive. Methods 22 of special genetic marker,known as her2 positive invasive breast cancer patients to give the bead sheet music combined paclitaxel of every 3 new adjuvant chemotherapy treatment scheme, parallel radical surgery, and the clinical efficacy and side reactions were evaluated. Results 22 patients after treatment, 13 cases complete remission, part of ease in 3 cases ,4 cases were stable, progress in 2 cases, the effective rate was 72.7% （16/22） , disease control rates for 90.9% （20/22） ;Richard completely ease 12 cases（ 54.6% ）. Adverse reaction was mainly bone marrow inhibition and gas- trointestinal reaction. Conclusion The bead sheet music combined paclitaxel of neoadjuvant chemotherapy treatment scheme special genetic marker,known as her2 positive can be the surgical treatment for breast cancer is better,and safe, has the high pathologic complete remission rate and efficient.